Classification of Colon Cancer Patients Based on the Methylation Patterns of Promoters |
Choi, Wonyoung
(Department of Integrated OMICS for Biomedical Science, Graduate School, Yonsei University)
Lee, Jungwoo (Department of Integrated OMICS for Biomedical Science, Graduate School, Yonsei University) Lee, Jin-Young (Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University) Lee, Sun-Min (Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University) Kim, Da-Won (Department of Integrated OMICS for Biomedical Science, Graduate School, Yonsei University) Kim, Young-Joon (Department of Integrated OMICS for Biomedical Science, Graduate School, Yonsei University) |
1 | Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-1558. DOI |
2 | Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010;466:869-873. DOI |
3 | Schweiger MR, Barmeyer C, Timmermann B. Genomics and epigenomics: new promises of personalized medicine for cancer patients. Brief Funct Genomics 2013;12:411-421. DOI |
4 | Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science 2015;349:1483-1489. DOI |
5 | Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 2013;339:1567-1570. DOI |
6 | Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005;2 Suppl 1:S4-S11. DOI |
7 | Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010;29:181-206. DOI |
8 | Breuer K, Foroushani AK, Laird MR, Chen C, Sribnaia A, Lo R, et al. InnateDB: systems biology of innate immunity and beyond: recent updates and continuing curation. Nucleic Acids Res 2013;41:D1228-D1233. DOI |
9 | Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054. DOI |
10 | Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-2087.e3. DOI |
11 | Horsthemke B. Epimutations in human disease. Curr Top Microbiol Immunol 2006;310:45-59. |
12 | Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013;14:16365-16385. DOI |
13 | Yuan W, Lopez Bernal A. Cyclic AMP signalling pathways in the regulation of uterine relaxation. BMC Pregnancy Childbirth 2007;7 Suppl 1:S10. DOI |
14 | Ligeti E, Welti S, Scheffzek K. Inhibition and termination of physiological responses by GTPase activating proteins. Physiol Rev 2012;92:237-272. DOI |
15 | Agid Y, Buzsaki G, Diamond DM, Frackowiak R, Giedd J, Girault JA, et al. How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 2007;6:189-201. DOI |
16 | Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev 2006;86:805-847. DOI |
17 | Goodchild RE, Grundmann K, Pisani A. New genetic insights highlight 'old' ideas on motor dysfunction in dystonia. Trends Neurosci 2013;36:717-725. DOI |
18 | Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007;7:79-94. DOI |
19 | Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002;3:383-394. DOI |
20 | Hitchins MP. Constitutional epimutation as a mechanism for cancer causality and heritability? Nat Rev Cancer 2015;15:625-634. DOI |
21 | Ritter SL, Hall RA. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol 2009;10:819-830. DOI |
![]() |